Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;15(3):376-385.
doi: 10.3988/jcn.2019.15.3.376.

Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample

Haichang Xin  1 , Linda A Harris  2 , Inmaculada B Aban  3 , Gary Cutter  4
Affiliations

Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample

Haichang Xin et al. J Clin Neurol. 2019 Jul.

Abstract

Background and purpose: Patients with refractory myasthenia gravis (MG) experience ongoing disease burden that might be reflected in their healthcare utilization. Here we examine the impact of refractory MG on healthcare utilization.

Methods: The 825 included participants were aged 18-64 years, enrolled in the Myasthenia Gravis Foundation of America Patient Registry between July 2013 and February 2018, and had been diagnosed with MG ≥2 years previously.

Results: Participants comprised 76 (9.2%) with refractory MG and 749 (90.8%) with nonrefractory MG. During the 6 months before enrollment, participants with refractory MG were significantly more likely than those with nonrefractory MG to have experienced at least one exacerbation [67.1% vs. 52.0%, respectively, p=0.01; odds ratio (OR)=1.882, 95% confidence interval (CI)=1.141-3.104], visited an emergency room at least once [43.4% vs. 27.1%, p<0.01; OR=2.065, 95% CI=1.276-3.343], been hospitalized overnight at least once (32.9% vs. 20.5%, p=0.01; OR=1.900, 95% CI=1.140-3.165), ever been admitted to an intensive care unit (ICU) (61.8% vs. 33.4%, p<0.01; OR=3.233, 95% CI=1.985-5.266), or ever required a feeding tube (21.1% vs. 9.1%, p<0.01; OR=2.671, 95% CI=1.457-4.896). A total of 75.8% younger females with refractory disease (<51 years, n=33) experienced at least one exacerbation, 69.7% had been admitted to an ICU, and 30.3% had required a feeding tube. For older females with refractory disease (≥51 years, n=33), 60.6%, 54.6%, and 6.1% experienced these outcomes, respectively (between-group differences were not significant).

Conclusions: Refractory MG is associated with higher disease burden and healthcare utilization than nonrefractory MG.

Keywords: disease exacerbations; healthcare resource utilization; myasthenia gravis; refractory disease.

PubMed Disclaimer

Conflict of interest statement

Linda A. Harris is employed by Alexion Pharmaceuticals, Inc.; Gary Cutter, Haichang Xin, and Inmaculada B. Aban are employed by the University of Alabama at Birmingham, which received financial support from Alexion for this study. Gary Cutter is also President of Pythagoras, Inc., a private consulting company located in Birmingham, AL, USA, and is Professor of Biostatistics at the School of Public Health at the University of Alabama at Birmingham. Gary Cutter has served as a member of consulting or advisory boards (Argenx, Atara Biotherapeutics, Axon, Biogen, BrainStorm Cell Therapeutics, Charleston Laboratories, Click Therapeutics, Genentech, Genzyme, GW Pharmaceuticals, Klein Buendel, MedDay Pharmaceuticals, MedImmune, Novartis, Roche, SciFluor Life Sciences, Somahlution, Teva, TG Therapeutics, and UT Houston), and data and safety monitoring boards [AMO Pharma, BioLineRx, Hisun USA, and Horizon Pharma, Merck, Merck/Pfizer, National Heart, Lung, and Blood Institute (NHLBI; Protocol Review Committee), Neurim Pharmaceuticals, National Institute of Child Health and Human Development (NICHD; OPRU Oversight Committee), Novartis, OPKO Biologics, Orphazyme, Reata Pharmaceuticals, Receptos/Celgene, Sanofi-Aventis, and Teva].

Figures

Fig. 1
Fig. 1. Criteria used for classifying refractory MG. MG-ADL: myasthenia gravis activities of daily living scale.
Fig. 2
Fig. 2. Flow chart showing selection process for the study sample. MG-ADL: myasthenia gravis activities of daily living scale.
Fig. 3
Fig. 3. Exacerbations in and healthcare resource utilization by participants with refractory MG and nonrefractory MG (A) and numbers of exacerbations and ER visits during the 6 months before enrollment in participants with refractory and nonrefractory MG (B). Frequencies of study variables were compared between participants with refractory and nonrefractory MG using χ2 tests for categorical variables and the number of exacerbations, and Fisher's exact test for the number of ER visits. p values are for comparisons between the refractory- and nonrefractory-MG groups, and were calculated after excluding data from participants with unknown/missing data. *During the 6 months before enrollment. ER: emergency room, ICU: intensive care unit, MG: myasthenia gravis.
Fig. 4
Fig. 4. Unadjusted ordinal logistic model examining the impact of refractory MG on exacerbations and healthcare resource utilization. *During the 6 months before enrollment. Analyses were based on fitting logistic models for binary outcomes except for when analyzing the numbers of exacerbations and ER visits, for which proportional-odds models for ordinal outcomes were fitted. CI: confidence interval, ER: emergency room, ICU: intensive care unit, MG: myasthenia gravis, OR: odds ratio.
Fig. 5
Fig. 5. Exacerbations in and healthcare resource utilization by younger and older female participants with refractory MG (A) and numbers of exacerbations and ER visits during the 6 months before enrollment in younger and older female participants with refractory MG (B). Frequencies of study variables were compared between participants with refractory and nonrefractory MG using χ2 tests for categorical variables and the number of exacerbations, and using Fisher's exact test for the number of ER visits. p values are for comparisons between the refractory- and nonrefractory-MG groups, and were calculated after excluding data from participants with unknown/missing data. *During the 6 months before enrollment. ER: emergency room, ICU: intensive care unit, MG: myasthenia gravis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150–151. - PubMed
    1. Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE, et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med. 2015;277:594–604. - PubMed
    1. Cetin H, Fülöp G, Zach H, Auff E, Zimprich F. Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society. Wien Klin Wochenschr. 2012;124:763–768. - PubMed
    1. Park SY, Lee JY, Lim NG, Hong YH. Incidence and prevalence of myasthenia gravis in Korea: a population-based study using the National Health Insurance claims database. J Clin Neurol. 2016;12:340–344. - PMC - PubMed
    1. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305:97–102. - PubMed